新開源(300109.SZ):參股公司永泰生物已通過香港聯交所聆訊
格隆匯6月8日丨新開源(300109.SZ)公佈,公司今日收到參股公司永泰生物的通知,永泰生物已通過香港聯合交易所有限公司(“香港聯交所”)聆訊,建銀國際和國信證券(香港)擔任其聯席保薦人。
永泰生物是中國一家領先的細胞免疫治療生物醫藥公司,專注於T細胞免疫治療藥物研究和商業化,核心在研產品EAL?屬於多靶點腫瘤細胞免疫治療產品,是中國首款獲准進入II期臨牀試驗的免疫細胞產品,在癌症治療臨牀應用方面具有逾十年的往績,並對多種癌症顯示了治療效果。
永泰生物產品鏈覆蓋了非基因改造細胞、基因改造細胞、腫瘤多靶點治療細胞、腫瘤單靶點治療細胞等全線腫瘤細胞免疫治療產品,除EAL®產品外,主要在研產品包括CAR-T細胞系列,TCR-T細胞系列等。
值得注意的是,永泰生物製藥有限公司(英文名:Immunotech Biopharm Ltd,簡稱“永泰生物”)擬在香港聯交所上市,公司持有永泰生物1.9%的股份,該事項對公司不構成重大影響,請投資者特別注意!
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.